Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation

被引:2
|
作者
Sung, Chao-Hsien [1 ]
Tsuang, Fon-Yih [2 ]
Lin, Chih-Peng [3 ]
Chan, Kuang-Cheng [3 ]
Chou, Wei-Han [3 ]
Wu, Chun-Yu [3 ]
机构
[1] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Dept Anesthesiol, New Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Neurosurg, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Anesthesiol, 7 Chung Shan S Rd, Taipei, Taiwan
关键词
CENTRAL-NERVOUS-SYSTEM; CANCER RECURRENCE; GLIOBLASTOMA; CELL; ANESTHESIA; SURVIVAL; CATECHOLAMINES; CYTOTOXICITY; PROPOFOL; SURGERY;
D O I
10.1038/s41598-021-95851-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
High-grade gliomas are notorious for a high recurrence rate even after curative resection surgery. Studies regarding the influence of scalp block on high-grade gliomas have been inconclusive, possibly because the condition's most important genetic mutation profile, namely the isocitrate dehydrogenase 1 (IDH1) mutation, had not been analyzed. Therefore, we conducted a single-center study including patients with high-grade glioma who underwent tumor resection between January 2014 and December 2019. Kaplan-Meier survival analysis revealed that scalp block was associated with longer progression-free survival (PFS; 15.17 vs. 10.77 months, p = 0.0018), as was the IDH1 mutation (37.37 vs. 10.90 months, p = 0.0149). Multivariate Cox regression analysis revealed that scalp block (hazard ratio: 0.436, 95% confidence interval: 0.236-0.807, p = 0.0082), gross total resection (hazard ratio: 0.405, 95% confidence interval: 0.227-0.721, p = 0.0021), and IDH1 mutation (hazard ratio: 0.304, 95% confidence interval: 0.118-0.784, p = 0.0138) were associated with better PFS. Our results demonstrate that application of scalp block, regardless of IDH1 profile, is an independent factor associated with longer PFS for patients with high-grade glioma.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages
    De, Ishani
    Steffen, Megan D.
    Clark, Paul A.
    Patros, Clayton J.
    Sokn, Emily
    Bishop, Stephanie M.
    Litscher, Suzanne
    Maklakova, Vilena I.
    Kuo, John S.
    Rodriguez, Fausto J.
    Collier, Lara S.
    CANCER RESEARCH, 2016, 76 (09) : 2552 - 2560
  • [32] High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis
    Zheng, Linmao
    Zhang, Mengni
    Hou, Jing
    Gong, Jing
    Nie, Ling
    Chen, Xueqin
    Zhou, Qiao
    Chen, Ni
    NEUROPATHOLOGY, 2020, 40 (06) : 599 - 605
  • [33] Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET
    Wang, Yang
    Fushimi, Yasutaka
    Arakawa, Yoshiki
    Shimizu, Yoichi
    Sano, Kohei
    Sakata, Akihiko
    Nakajima, Satoshi
    Okuchi, Sachi
    Hinoda, Takuya
    Oshima, Sonoko
    Otani, Sayo
    Ishimori, Takayoshi
    Tanji, Masahiro
    Mineharu, Yohei
    Yoshida, Kazumichi
    Nakamoto, Yuji
    JAPANESE JOURNAL OF RADIOLOGY, 2023, 41 (11) : 1255 - 1264
  • [34] Hypoxia-related molecules HIF-1α, CA9, and osteopontin Predictors of survival in patients with high-grade glioma
    Erpolat, O. P.
    Gocun, P. U.
    Akmansu, M.
    Ozgun, G.
    Akyol, G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 (02) : 147 - 154
  • [35] PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma
    Kurz, Sylvia C.
    Cabrera, Lais P.
    Hastie, David
    Huang, Raymond
    Unadkat, Prashin
    Rinne, Mikael
    Nayak, Lakshmi
    Lee, Eudocia Q.
    Reardon, David A.
    Wen, Patrick Y.
    NEUROLOGY, 2018, 91 (14) : E1355 - E1359
  • [36] Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer
    Fujii, Nakanori
    Hoshii, Yoshinobu
    Hirata, Hiroshi
    Mori, Junichi
    Shimizu, Kosuke
    Kobayashi, Keita
    Kawai, Yoshihisa
    Inoue, Ryo
    Yamamoto, Yoshiaki
    Matsumoto, Hiroaki
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (06) : 560 - 567
  • [37] Health Related Quality of Life in Adult Low and High-Grade Glioma Patients Using the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) and Neuro-QOL Assessments
    Gabel, Nicolette
    Altshuler, David B.
    Brezzell, Amanda
    Briceno, Emily M.
    Boileau, Nicholas R.
    Miklja, Zachary
    Kluin, Karen
    Ferguson, Thomas
    McMurray, Kaitlin
    Wang, Lin
    Smith, Sean R.
    Carlozzi, Noelle E.
    Hervey-Jumper, Shawn L.
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [38] Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients
    Chen, Xi
    Yan, Yuanliang
    Zhou, Jianhua
    Huo, Lei
    Qian, Long
    Zeng, Shuangshuang
    Li, Zhi
    Wei, Jie
    Xu, Zhijie
    Gong, Zhicheng
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (20)
  • [39] Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial
    Chiocca, E. Antonio
    Yu, John S.
    Lukas, Rimas V.
    Solomon, Isaac H.
    Ligon, Keith L.
    Nakashima, Hiroshi
    Triggs, Daniel A.
    Reardon, David A.
    Wen, Patrick
    Stopa, Brittany M.
    Naik, Ajay
    Rudnick, Jeremy
    Hu, Jethro L.
    Kumthekar, Priya
    Yamini, Bakhtiar
    Buck, Jill Y.
    Demars, Nathan
    Barrett, John A.
    Gelb, Arnold B.
    Zhou, John
    Lebel, Francois
    Cooper, Laurence J. N.
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (505)
  • [40] Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma
    Wang, Michael H.
    Roa, Wilson
    Wachowicz, Keith
    Yahya, Atiyah
    Murtha, Albert
    Amanie, John
    Chainey, Jonathan
    Quon, Harvey
    Ghosh, Sunita
    Patel, Samir
    ANTICANCER RESEARCH, 2022, 42 (05) : 2665 - 2673